...Thomas Weber; Andreas Schmidberger; Kinga Ligeti; Marcus Bauer; Andreas Rosenwald; Lutz P. Müller Introduction: Skin rash is a first symptom of acute graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (ASCT) but can also be caused by viruses. The relevance of virus DNA...

...Vaishali Sanchorawala AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success...

... SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S: National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood...

... is not statistically different from the normal population as (SIR 0.89) and did not change when the earlier time period was compared with the later time period (data not shown). Fig. 4 Impact of stem cell transplantation (SCT). Fig. 4. Impact of stem cell transplantation (SCT). Fig. 3 Survival...

... in diuretic use and wall thickness. Patients were treated according to standard chemotherapy regimens and divided into 3 groups based on the first-line treatment strategy (high-dose melphalan with autologous stem cell transplantation (HD-ASCT), non-HD-ASCT, or no treatment). The non-HD-ASCT group...

... because they are commonly lumped into either pediatric or adult subgroups. Methods: Here we review acute and chronic issues surrounding hematopoietic stem cell transplantation (HSCT) with a focus on the AYA age group. Results: HSCT is a commonly used treatment modality for patients with certain types...

...-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Among the various sources of MSCs that have immunomodulatory effects in vitro, only placenta-derived MSCs (PD-MSCs) have not been evaluated in an in vivo model of GVHD. In this study, we investigated the immunomodulatory...

... by allogeneic hematopoietic stem cell transplantation (allo-HSCT) and IM maintenance treatment after allo-HSCT. Results: Both patients achieved long-term disease-free survival with complete hematologic response, complete molecular response, and complete cytogenetic response for 44 and 48 months, respectively...

...Mariangela Palladino; Luca Laurenti; Patrizia Chiusolo; Paola Piccioni; Idanna Innocenti; Michela Tarnani; Federica Sorà; Simona Sica; Giuseppe Leone Few data are available to date on the dose of oral valganciclovir as cytomegalovirus (CMV) preemptive therapy in stem cell transplantation patients...

... allogeneic stem cell transplantation. He was severely neutropenic after the conditioning for transplantation, but he had no history of fungal infection. Five days after the transplantation, he developed IP A in the left upper lung, complicated by left subclavian artery occlusion. Extensive chronic graft...

... to in the content or advertisements. Granulocyte colony-stimulating factor Gene chip array Expression level Normal donors Stem cell transplantation Granulocyte colony-stimulating factor (G-CSF) is used widely for various indications in hematology and oncology [ 1,2,3 ]. One of the proven...

... evolution Cytogenetics Myelodysplastic syndrome Ring chromosome 1 Stem cell transplantation Donor lymphocyte infusion Cytogenetic abnormalities are known to occur in bone marrow (BM) cells in about 50% of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [ 1,2,3...

...Christian Thiede; Martin Bornhäuser; Gerhard Ehninger Analysis of donor chimerism has become a routine method for the documentation of engraftment after allogeneic hematopoietic stem cell transplantation (HSCT). In recent years several groups have also focused on the application of this technique...

...Avichai Shimoni; Arnon Nagler Allogeneic stem cell transplantation (SCT) is a potentially curative therapy for a variety of hematological malignancies; however, relapse and treatment-related toxicities are major obstacles to cure. Nonmyeloablative and reduced-intensity conditioning regimens were...

...Hans-Jochem Kolb; Christoph Schmid; Xiao Chen; Anja Woiciechowski; Marie Roskrow; Martin Weber; Wolfgang Guenther; Georg Ledderose; Michael Schleuning Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect...